{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that data was not available as the current PK sampling schedule made the estimation of Vz/F incalculable due to long half-life of major metabolite of Niraparib (M1).","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"NA indicates that data was not available as the current PK sampling schedule made the estimation of Vz/F incalculable due to long half-life of major metabolite of Niraparib (M1).","groupId":"OG001","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Blood samples were planned to be collected for to determine Vz/F of major metabolite (M1) of Niraparib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 1: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 1: Niraparib 300 mg + Pembrolizumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Analysis Set. The current PK sampling schedule made the estimation of Vz/F incalculable due to long half life of major metabolite of Niraparib (M1).","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)","title":"Phase 1: Volume of Distribution (Vz/F) of Major Metabolite of Niraparib (M1)","type":"SECONDARY","unitOfMeasure":"Liters"}